PMID- 35951145
OWN - NLM
STAT- MEDLINE
DCOM- 20220929
LR  - 20221003
IS  - 1573-4978 (Electronic)
IS  - 0301-4851 (Linking)
VI  - 49
IP  - 10
DP  - 2022 Oct
TI  - Effect of methylenetetrahydrofolate reductase C677T polymorphism on serum folate 
      but not vitamin B12 levels in patients with H-type hypertension.
PG  - 9535-9541
LID - 10.1007/s11033-022-07844-w [doi]
AB  - BACKGROUND: Hyperhomocysteinemia (HHcy) is a common complication in Chinese 
      hypertensive patients and associated with methylenetetrahydrofolate reductase 
      (MTHFR) C677T polymorphism, folate, and vitamin B12 (Vit B12) status. This study 
      evaluated the associations of MTHFR C677T polymorphism, folate, and Vit B12 with 
      H-type hypertension. METHODS AND RESULTS: 887 eligible patients with essential 
      hypertension were included. Patients were divided into two groups according to 
      the Hcy level, the H-type hypertension group and the normal hypertension group. 
      Related risk factors such as MTHFR polymorphism, folate and Vit B12 status were 
      analyzed in the two groups. Age, gender, SBP, DBP, MTHFR C677T genotype, folate 
      and Vit B12 differed significantly between H-type hypertension and normal 
      hypertension groups (P < 0.05). MTHFR 677TT variant, gender, folate, and Vit B12 
      were independent risk factors for the occurrence of H-type hypertension. The risk 
      for TT carriers was 8 times higher than that of CC and CT carriers [OR (95% CI) 
      8.248 (5.274-12.899)]. Male patients had almost fivefold higher odds than female 
      patients [OR (95% CI) 4.923 (2.741-8.842)]. Folate level of patients with H-type 
      hypertension decreased with the C to T substitution of MTFHR C677T gene 
      (P < 0.05), while Vit B12 level was not associated with the gene (P > 0.05). 
      CONCLUSIONS: MTHFR 677TT variant, gender, folate, and Vit B12 were risk factors 
      for the occurrence of H-type hypertension. Folate but not Vit B12 was associated 
      with MTFHR C677T polymorphism in patients with H-type hypertension. Accordingly, 
      the above factors may be considered in the prevention and treatment of 
      hypertension.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer Nature B.V.
FAU - Ma, Lijuan
AU  - Ma L
AD  - Department of Pharmacy, Xinjiang Medical University Affiliated First Hospital, 
      Urumqi, 830011, China.
AD  - The Precision Medicine Center of Xinjiang Medical University, Urumqi, 830011, 
      China.
FAU - Li, Jing
AU  - Li J
AD  - Department of Pharmacy, Xinjiang Medical University Affiliated First Hospital, 
      Urumqi, 830011, China.
FAU - Yuan, Yuan
AU  - Yuan Y
AD  - Department of Pharmacy, Xinjiang Medical University Affiliated First Hospital, 
      Urumqi, 830011, China.
AD  - The Precision Medicine Center of Xinjiang Medical University, Urumqi, 830011, 
      China.
FAU - Chen, Wenwen
AU  - Chen W
AD  - Department of Pharmacy, Xinjiang Medical University Affiliated First Hospital, 
      Urumqi, 830011, China.
FAU - Zhao, Jun
AU  - Zhao J
AD  - Department of Pharmacy, Xinjiang Medical University Affiliated First Hospital, 
      Urumqi, 830011, China. xjmufh13046@163.com.
AD  - The Precision Medicine Center of Xinjiang Medical University, Urumqi, 830011, 
      China. xjmufh13046@163.com.
LA  - eng
GR  - 2017YFC0910001/National Key Development Plan for Precision Medicine Research/
PT  - Journal Article
DEP - 20220811
PL  - Netherlands
TA  - Mol Biol Rep
JT  - Molecular biology reports
JID - 0403234
RN  - 0 (Antihypertensive Agents)
RN  - 0LVT1QZ0BA (Homocysteine)
RN  - 935E97BOY8 (Folic Acid)
RN  - EC 1.5.1.20 (Methylenetetrahydrofolate Reductase (NADPH2))
RN  - P6YC3EG204 (Vitamin B 12)
SB  - IM
MH  - Antihypertensive Agents
MH  - Female
MH  - Folic Acid
MH  - Genotype
MH  - Homocysteine
MH  - Humans
MH  - *Hypertension/genetics
MH  - Male
MH  - *Methylenetetrahydrofolate Reductase (NADPH2)/genetics
MH  - Vitamin B 12
OTO - NOTNLM
OT  - Folate
OT  - H-type hypertension
OT  - Homocysteine
OT  - Methylenetetrahydrofolate reductase
OT  - Vitamin B12
EDAT- 2022/08/12 06:00
MHDA- 2022/09/30 06:00
CRDT- 2022/08/11 11:21
PHST- 2022/06/07 00:00 [received]
PHST- 2022/08/04 00:00 [accepted]
PHST- 2022/08/12 06:00 [pubmed]
PHST- 2022/09/30 06:00 [medline]
PHST- 2022/08/11 11:21 [entrez]
AID - 10.1007/s11033-022-07844-w [pii]
AID - 10.1007/s11033-022-07844-w [doi]
PST - ppublish
SO  - Mol Biol Rep. 2022 Oct;49(10):9535-9541. doi: 10.1007/s11033-022-07844-w. Epub 
      2022 Aug 11.